Revenue Breakdown
Composition ()
No data
Revenue Streams
Vanda Pharmaceuticals Inc (VNDA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Fanapt, accounting for 55.5% of total sales, equivalent to $31.25M. Other significant revenue streams include Hetlioz and PONVORY. Understanding this composition is critical for investors evaluating how VNDA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Vanda Pharmaceuticals Inc maintains a gross margin of 91.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -55.61%, while the net margin is -40.15%. These profitability ratios, combined with a Return on Equity (ROE) of -16.72%, provide a clear picture of how effectively VNDA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, VNDA competes directly with industry leaders such as SIGA and ACRS. With a market capitalization of $459.18M, it holds a significant position in the sector. When comparing efficiency, VNDA's gross margin of 91.63% stands against SIGA's 61.75% and ACRS's 25.77%. Such benchmarking helps identify whether Vanda Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
